VTVT

vTv Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates for the treatment of diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin, an oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are exploring multiple molecules targeting various chronic diseases. The company is based in High Point, North Carolina.